NCT02650193 - A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions

Non-metastatic Breast Cancer

Interventions

DRUG

HSP-130

Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg

Trial Locations (7)

1122

Országos Onkológiai Intézet, Budapest

3529

CRU Hungary Kft.,CRU Early Phase Unit, Miskolci Semmelweis Kórház és Egyetemi Oktató Kórház, Miskolc

4032

Debreceni Egyetem Klinikai Központ, ÁOK, Onkológiai Klinika, Debrecen

25198

Hospital Universitario Arnau de Vilanova, Lleida

28050

START Madrid - CIOCC, Unidad de fases 1 planta 3, Hospital Universitario HM Sanchinarro, Madrid

28942

Hospital Universitario de Fuenlabrada, Servicio de oncologia, Fuenlanbrada

46015

Hospital Arnau de Vilanova. planta 6, unidad de Oncología, Valencia